Artitaya Lophatananon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Artitaya Lophatananon has a total of 377 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth Muir
Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK
34 shared publications - Emma J. Crosbie
University of Manchester
5 shared publications - Jawaria Parvaiz
Gynaecological Oncology Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom
5 shared publications - Jingmei Li
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
5 shared publications - Olivia Aurangzeb
Gynaecological Oncology Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, United Kingdom
5 shared publications - Sarah J. Kitson
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK
5 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8224
Environmental Pollution, Biomarkers, and Dementia: An Evidence Review
With rapid global urbanization, exposure to environmental pollutants has emerged as a potentially important determinant of cognitive health. We therefore systematically searched PubMed and Embase for epidemiological studies published between 2020 and 2026 and reviewed the associations between ambient air pollution, environmental chemical pollutants, and dementia. Evidence on potential biological mechanisms was identified to support the biological plausibility of the observed associations. Epidemiological evidence indicated that long-term exposure to particulate matter (PM2.5), nitrogen oxides (NO2), and black carbon was associated with increased dementia risk, whereas evidence for PM10 and ozone remained inconclusive. Plastic-associated chemicals, including phthalates and bisphenols, heavy metals (Lead-Pb and Cadmium-Cd), and per- and polyfluoroalkyl substances (PFOS), were linked with poorer cognitive function and dementia-related outcomes; findings for pesticides and herbicides were inconsistent. In terms of possible mechanisms, molecular evidence suggests that air pollution and environmental chemical pollutants may promote oxidative stress, neuroinflammation, metabolic dysfunction, Alzheimer’s disease pathology, and vascular damage, although evidence for epigenetic mechanisms remains more limited for environmental chemical pollutants. Overall, the evidence remains limited due to the predominance of observational studies. Future research that integrates molecular biomarkers and causal inference techniques is needed to better understand the role of environmental pollutants in dementia.
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8224
Open AccessEnvironmental Pollution, Biomarkers, and Dementia: An Evidence Review
With rapid global urbanization, exposure to environmental pollutants has emerged as a potentially important determinant of cognitive health. We therefore systematically searched PubMed and Embase for epidemiological studies published between 2020 and 2026 and reviewed the associations between ambient air pollution, environmental chemical pollutants, and dementia. Evidence on potential biological mechanisms was identified to support the biological plausibility of the observed associations. Epidemiological evidence indicated that long-term exposure to particulate matter (PM2.5), nitrogen oxides (NO2), and black carbon was associated with increased dementia risk, whereas evidence for PM10 and ozone remained inconclusive. Plastic-associated chemicals, including phthalates and bisphenols, heavy metals (Lead-Pb and Cadmium-Cd), and per- and polyfluoroalkyl substances (PFOS), were linked with poorer cognitive function and dementia-related outcomes; findings for pesticides and herbicides were inconsistent. In terms of possible mechanisms, molecular evidence suggests that air pollution and environmental chemical pollutants may promote oxidative stress, neuroinflammation, metabolic dysfunction, Alzheimer’s disease pathology, and vascular damage, although evidence for epigenetic mechanisms remains more limited for environmental chemical pollutants. Overall, the evidence remains limited due to the predominance of observational studies. Future research that integrates molecular biomarkers and causal inference techniques is needed to better understand the role of environmental pollutants in dementia.
- Open Access
Causal roles of phenotypic age acceleration and metabolic health on dementia: a Mendelian randomisation and structure learning study
Summary: Background: Phenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes. Whether these associations are causal and reflect the exposures, constituent biomarkers, or both remains unclear. Methods: This study included UK Biobank participants of White British genetic ancestry. MetaboHealth was derived from nuclear magnetic resonance (NMR) metabolomics and PhenoAgeAccel from clinical biomarkers and chronological age. Genome-wide association studies (GWAS) were conducted for MetaboHealth (n=272 568) and PhenoAgeAccel (n=274 077). Independent genome-wide significant variants were used as genetic instruments in two-sample Mendelian randomisation (MR) with FinnGen all-cause dementia summary statistics. Inverse-variance weighting was the primary MR method. Causal network analysis estimated relationships among constituent biomarkers and dementia. Findings: GWAS identified 126 and 141 independent genome-wide significant variants for MetaboHealth and PhenoAgeAccel, of which 109 and 141 were retained as genetic instruments. MR found no evidence of a causal effect of genetically predicted MetaboHealth (per unit: OR 0·83, 95% CI 0·49–1·42; p=0·51) or PhenoAgeAccel (per year: OR 0·99, 95% CI 0·95–1·02; p=0·44) on all-cause dementia, with consistent findings across sensitivity analyses and robust MR methods. Lower lymphocyte percentage and higher NMR-derived glucose had direct relationships with dementia in the joint constituent-biomarker network. Interpretation: MR provided no evidence that either composite exposure causally influenced dementia. The network prioritised lymphocyte percentage and NMR-derived glucose, supporting examination of composite exposures alongside their constituent biomarkers. Funding: NIHR, UKRI, MRC, UK Dementia Research Institute, Innovate UK, and European Union. Full funding details are provided in the acknowledgements. Research in context: Evidence before this study: We searched PubMed from database inception to July 11, 2026, without language restrictions, using combinations of the terms “dementia”, “Alzheimer’s disease”, “vascular dementia”, “biological ageing”, “phenotypic age”, “PhenoAge”, “PhenoAgeAccel”, “MetaboHealth”, “metabolomics”, “genome-wide association study”, “Mendelian randomisation”, and “causal network”. Previous GWAS characterised the genetic architecture of PhenoAgeAccel and MetaboHealth. Longitudinal studies linked PhenoAgeAccel, derived from PhenoAge, to incident all-cause, young-onset, and late-onset dementia, dementia subtypes, cognition, and brain structure; MetaboHealth was associated with poorer cognitive performance, 10-year cognitive decline, and reduced functional independence. Related PhenoAge-based measures have also been studied in relation to modifiable factors and intervention response. Genetic causal evidence remained limited: one two-sample MR study found no evidence that PhenoAgeAccel affected Alzheimer’s disease or vascular dementia, while previous causal-discovery research placed Phenotypic Age within a dementia network without examining its constituent biomarkers. Added value of this study: To our knowledge, this is the first study to genetically evaluate PhenoAgeAccel and MetaboHealth as composite exposures and then deconstruct their constituent biomarker relationships using causal network analysis in dementia. It also provides the first large-scale GWAS of MetaboHealth using the complete Phase 3 UK Biobank Nightingale dataset. The expanded GWAS identified additional loci and enlarged the available genetic instrument sets, while the network analysis resolved the constituent biomarker structure underlying both composite exposures. Implications of all available evidence: For causal investigation, analysing PhenoAgeAccel and MetaboHealth alongside their constituent biomarkers reveals relationships obscured within the composite exposures. This does not preclude their use for prediction or risk stratification. Lymphocyte percentage and NMR-derived glucose therefore warrant further investigation as potential indicators of immune and metabolic pathways relevant to dementia.
Open AccessCausal roles of phenotypic age acceleration and metabolic health on dementia: a Mendelian randomisation and structure learning study
Summary: Background: Phenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes. Whether these associations are causal and reflect the exposures, constituent biomarkers, or both remains unclear. Methods: This study included UK Biobank participants of White British genetic ancestry. MetaboHealth was derived from nuclear magnetic resonance (NMR) metabolomics and PhenoAgeAccel from clinical biomarkers and chronological age. Genome-wide association studies (GWAS) were conducted for MetaboHealth (n=272 568) and PhenoAgeAccel (n=274 077). Independent genome-wide significant variants were used as genetic instruments in two-sample Mendelian randomisation (MR) with FinnGen all-cause dementia summary statistics. Inverse-variance weighting was the primary MR method. Causal network analysis estimated relationships among constituent biomarkers and dementia. Findings: GWAS identified 126 and 141 independent genome-wide significant variants for MetaboHealth and PhenoAgeAccel, of which 109 and 141 were retained as genetic instruments. MR found no evidence of a causal effect of genetically predicted MetaboHealth (per unit: OR 0·83, 95% CI 0·49–1·42; p=0·51) or PhenoAgeAccel (per year: OR 0·99, 95% CI 0·95–1·02; p=0·44) on all-cause dementia, with consistent findings across sensitivity analyses and robust MR methods. Lower lymphocyte percentage and higher NMR-derived glucose had direct relationships with dementia in the joint constituent-biomarker network. Interpretation: MR provided no evidence that either composite exposure causally influenced dementia. The network prioritised lymphocyte percentage and NMR-derived glucose, supporting examination of composite exposures alongside their constituent biomarkers. Funding: NIHR, UKRI, MRC, UK Dementia Research Institute, Innovate UK, and European Union. Full funding details are provided in the acknowledgements. Research in context: Evidence before this study: We searched PubMed from database inception to July 11, 2026, without language restrictions, using combinations of the terms “dementia”, “Alzheimer’s disease”, “vascular dementia”, “biological ageing”, “phenotypic age”, “PhenoAge”, “PhenoAgeAccel”, “MetaboHealth”, “metabolomics”, “genome-wide association study”, “Mendelian randomisation”, and “causal network”. Previous GWAS characterised the genetic architecture of PhenoAgeAccel and MetaboHealth. Longitudinal studies linked PhenoAgeAccel, derived from PhenoAge, to incident all-cause, young-onset, and late-onset dementia, dementia subtypes, cognition, and brain structure; MetaboHealth was associated with poorer cognitive performance, 10-year cognitive decline, and reduced functional independence. Related PhenoAge-based measures have also been studied in relation to modifiable factors and intervention response. Genetic causal evidence remained limited: one two-sample MR study found no evidence that PhenoAgeAccel affected Alzheimer’s disease or vascular dementia, while previous causal-discovery research placed Phenotypic Age within a dementia network without examining its constituent biomarkers. Added value of this study: To our knowledge, this is the first study to genetically evaluate PhenoAgeAccel and MetaboHealth as composite exposures and then deconstruct their constituent biomarker relationships using causal network analysis in dementia. It also provides the first large-scale GWAS of MetaboHealth using the complete Phase 3 UK Biobank Nightingale dataset. The expanded GWAS identified additional loci and enlarged the available genetic instrument sets, while the network analysis resolved the constituent biomarker structure underlying both composite exposures. Implications of all available evidence: For causal investigation, analysing PhenoAgeAccel and MetaboHealth alongside their constituent biomarkers reveals relationships obscured within the composite exposures. This does not preclude their use for prediction or risk stratification. Lymphocyte percentage and NMR-derived glucose therefore warrant further investigation as potential indicators of immune and metabolic pathways relevant to dementia.
- Open Access
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7707
Metabolic Dysfunction and Related Dietary Exposures in Relation to Pancreatic Cancer Risk: A Review of the Evidence
Pancreatic cancer is a highly lethal malignancy with an increasing global incidence. Although metabolic dysfunction has been implicated in pancreatic cancer risk, the strength and consistency of evidence across different metabolic traits remain uncertain. Evidence for dietary exposures related to metabolic regulation is also less clearly established. This umbrella review synthesised evidence from systematic reviews, meta-analyses, and umbrella reviews evaluating metabolic dysfunction and related dietary exposures in relation to pancreatic cancer risk. A systematic search of PubMed, Web of Science, and PROSPERO identified reviews published between 1 January 2021 and 1 February 2026. Seventeen reviews met the inclusion criteria. The primary search focused on metabolic dysfunction. Dietary exposures identified during the screening process were retained as a secondary evidence domain when they were considered relevant to glycaemic regulation, insulin response, adiposity, or wider metabolic health. Primary-study overlap was slight, with an overall corrected covered area (CCA) of 1.59% and weighted corrected covered area (wCCA) of 1.40%; within the principal evidence domains of adiposity-related exposures and metabolic dysfunction, the CCA and wCCA were 1.15% and 1.81%, respectively. Metabolic dysfunction demonstrated the strongest and most consistent associations with pancreatic cancer risk. Metabolic syndrome, diabetes mellitus, hyperglycaemia, and abdominal obesity were graded as probable evidence. Hyperglycaemia showed the strongest component-level association (RR = 1.55, 95% CI: 1.42–1.70), while diabetes mellitus was consistently associated with increased risk across both cohort and case–control studies. Abdominal obesity, assessed using waist circumference and waist-to-hip ratio, was also positively associated with risk. General obesity, prediabetes, and reduced HDL cholesterol were graded as limited/suggestive evidence, whereas hypertriglyceridaemia was graded as limited/no conclusion. Related dietary exposures generally showed weaker and less consistent associations, with no exposure supported by convincing evidence. Overall, pancreatic cancer risk was more consistently associated with systemic metabolic dysfunction, particularly impaired glucose regulation, diabetes, metabolic syndrome, and abdominal adiposity, than with the related dietary exposures examined. However, the evidence remains predominantly observational and does not establish causality.
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7707
Open AccessMetabolic Dysfunction and Related Dietary Exposures in Relation to Pancreatic Cancer Risk: A Review of the Evidence
Pancreatic cancer is a highly lethal malignancy with an increasing global incidence. Although metabolic dysfunction has been implicated in pancreatic cancer risk, the strength and consistency of evidence across different metabolic traits remain uncertain. Evidence for dietary exposures related to metabolic regulation is also less clearly established. This umbrella review synthesised evidence from systematic reviews, meta-analyses, and umbrella reviews evaluating metabolic dysfunction and related dietary exposures in relation to pancreatic cancer risk. A systematic search of PubMed, Web of Science, and PROSPERO identified reviews published between 1 January 2021 and 1 February 2026. Seventeen reviews met the inclusion criteria. The primary search focused on metabolic dysfunction. Dietary exposures identified during the screening process were retained as a secondary evidence domain when they were considered relevant to glycaemic regulation, insulin response, adiposity, or wider metabolic health. Primary-study overlap was slight, with an overall corrected covered area (CCA) of 1.59% and weighted corrected covered area (wCCA) of 1.40%; within the principal evidence domains of adiposity-related exposures and metabolic dysfunction, the CCA and wCCA were 1.15% and 1.81%, respectively. Metabolic dysfunction demonstrated the strongest and most consistent associations with pancreatic cancer risk. Metabolic syndrome, diabetes mellitus, hyperglycaemia, and abdominal obesity were graded as probable evidence. Hyperglycaemia showed the strongest component-level association (RR = 1.55, 95% CI: 1.42–1.70), while diabetes mellitus was consistently associated with increased risk across both cohort and case–control studies. Abdominal obesity, assessed using waist circumference and waist-to-hip ratio, was also positively associated with risk. General obesity, prediabetes, and reduced HDL cholesterol were graded as limited/suggestive evidence, whereas hypertriglyceridaemia was graded as limited/no conclusion. Related dietary exposures generally showed weaker and less consistent associations, with no exposure supported by convincing evidence. Overall, pancreatic cancer risk was more consistently associated with systemic metabolic dysfunction, particularly impaired glucose regulation, diabetes, metabolic syndrome, and abdominal adiposity, than with the related dietary exposures examined. However, the evidence remains predominantly observational and does not establish causality.
- Open Access
- 1 April 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (2) , 22
Epigenetic Age Feedback as a Catalyst for Sustained Lifestyle Change: One-Year Results from the EU iHelp Study
Background: Sustaining long-term lifestyle change remains a major challenge in preventive health. Epigenetic clocks offer a dynamic, modifiable measure of biological ageing that may enhance motivation when returned to individuals. Objectives: This study had two aims: (1) to evaluate whether personalised health reports integrating epigenetic age, polygenic cancer risk scores, and lifestyle metrics could motivate sustained behavioural change; and (2) to examine variability across epigenetic clock generations to inform the selection of a suitable model for participant feedback. Methods: A total of 178 adults were recruited via the Graham Fulford Charitable Trust community testing programme, and 91 completed a one-year follow-up survey assessing behavioural, psychological, and knowledge-related outcomes. DNA methylation data from 140 samples were used to compare 14 epigenetic clocks across four generations. Results: Most participants reported positive lifestyle changes, including feeling healthier (72.5%), increased physical activity (60.4%), and improved diet (47.3%). Gains were also observed in health knowledge (63.7%) and psychological well-being (31.9%). Epigenetic clock comparisons revealed substantial heterogeneity across models. Zhang2019-BLUP was selected as a stable and interpretable measure of biological age that can be readily communicated to participants, supporting empowerment and improved health literacy, rather than serving only as a risk prediction metric. Conclusions: Personalised biomarker feedback including epigenetic age combined with lifestyle and wearable data can support self-reported improvements in health-related behaviours. Community-based delivery through trusted local networks proved effective. The marked variation between epigenetic clocks highlights the importance of selecting models designed for clear communication when used in public-facing health interventions.
- 1 April 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (2) , 22
Open AccessEpigenetic Age Feedback as a Catalyst for Sustained Lifestyle Change: One-Year Results from the EU iHelp Study
Background: Sustaining long-term lifestyle change remains a major challenge in preventive health. Epigenetic clocks offer a dynamic, modifiable measure of biological ageing that may enhance motivation when returned to individuals. Objectives: This study had two aims: (1) to evaluate whether personalised health reports integrating epigenetic age, polygenic cancer risk scores, and lifestyle metrics could motivate sustained behavioural change; and (2) to examine variability across epigenetic clock generations to inform the selection of a suitable model for participant feedback. Methods: A total of 178 adults were recruited via the Graham Fulford Charitable Trust community testing programme, and 91 completed a one-year follow-up survey assessing behavioural, psychological, and knowledge-related outcomes. DNA methylation data from 140 samples were used to compare 14 epigenetic clocks across four generations. Results: Most participants reported positive lifestyle changes, including feeling healthier (72.5%), increased physical activity (60.4%), and improved diet (47.3%). Gains were also observed in health knowledge (63.7%) and psychological well-being (31.9%). Epigenetic clock comparisons revealed substantial heterogeneity across models. Zhang2019-BLUP was selected as a stable and interpretable measure of biological age that can be readily communicated to participants, supporting empowerment and improved health literacy, rather than serving only as a risk prediction metric. Conclusions: Personalised biomarker feedback including epigenetic age combined with lifestyle and wearable data can support self-reported improvements in health-related behaviours. Community-based delivery through trusted local networks proved effective. The marked variation between epigenetic clocks highlights the importance of selecting models designed for clear communication when used in public-facing health interventions.
- Open Access
- 16 February 2026
- Published by Oxford University Press (OUP) in Environmental Epigenetics
- Vol. 12 (1)
Epigenetic mechanisms linking hexavalent chromium exposure to pancreatic cancer risk: a systematic review
Pancreatic cancer remains one of the most lethal malignancies, largely due to late diagnosis and limited treatment options. Hexavalent chromium (Cr(VI)) is a well-established environmental and occupational carcinogen, and emerging epidemiological observations have raised questions about its potential involvement in cancers beyond the lung. This systematic review synthesizes current evidence on the epigenetic effects of Cr(VI) exposure, including DNA methylation, histone modifications, and microRNA dysregulation, and evaluates whether these mechanisms converge on pathways relevant to pancreatic carcinogenesis. A structured literature search of EMBASE and PubMed (including MEDLINE) identified 11 studies that met predefined inclusion criteria. Across these studies, Cr(VI) exposure was consistently associated with hypermethylation of tumour suppressor genes (including MLH1 and RAD51), alterations in histone methylation (such as increased H3K9me2), and dysregulation of oncogenic microRNAs including miR-3940-5p. Collectively, these epigenetic alterations affect processes central to carcinogenesis, including DNA repair, genomic stability, inflammatory signalling, and cellular stress responses. Notably, several of the genes affected by Cr(VI) exposure such as MLH1, RAD51, CD44, and Nupr1 are well-recognized contributors to pancreatic ductal adenocarcinoma (PDAC) development. Although none of the identified studies directly examined Cr(VI)-associated epigenetic changes in pancreatic tissue or pancreatic cell systems, the convergence of Cr(VI)-induced epigenetic alterations on molecular pathways central to PDAC biology highlights a set of biologically plausible and testable hypotheses linking chromium exposure to pancreatic cancer risk. Together, the available evidence suggests that Cr(VI) exposure could plausibly promote pancreatic carcinogenesis through epigenetic silencing of DNA repair pathways and activation of stress-response and stemness-associated signalling networks. By integrating findings across diverse experimental systems, this review identifies mechanistic intersections between chromium-induced epigenetic dysregulation and established drivers of PDAC. These findings highlight a clear opportunity for targeted investigation of Cr(VI)-associated epigenetic signatures in pancreatic-relevant experimental models and in chromium-exposed human populations. Such studies could determine whether environmentally induced epigenetic alterations contribute to pancreatic cancer susceptibility and may reveal previously under-recognized environmental drivers of pancreatic carcinogenesis.
- 16 February 2026
- Published by Oxford University Press (OUP) in Environmental Epigenetics
- Vol. 12 (1)
Open AccessEpigenetic mechanisms linking hexavalent chromium exposure to pancreatic cancer risk: a systematic review
Pancreatic cancer remains one of the most lethal malignancies, largely due to late diagnosis and limited treatment options. Hexavalent chromium (Cr(VI)) is a well-established environmental and occupational carcinogen, and emerging epidemiological observations have raised questions about its potential involvement in cancers beyond the lung. This systematic review synthesizes current evidence on the epigenetic effects of Cr(VI) exposure, including DNA methylation, histone modifications, and microRNA dysregulation, and evaluates whether these mechanisms converge on pathways relevant to pancreatic carcinogenesis. A structured literature search of EMBASE and PubMed (including MEDLINE) identified 11 studies that met predefined inclusion criteria. Across these studies, Cr(VI) exposure was consistently associated with hypermethylation of tumour suppressor genes (including MLH1 and RAD51), alterations in histone methylation (such as increased H3K9me2), and dysregulation of oncogenic microRNAs including miR-3940-5p. Collectively, these epigenetic alterations affect processes central to carcinogenesis, including DNA repair, genomic stability, inflammatory signalling, and cellular stress responses. Notably, several of the genes affected by Cr(VI) exposure such as MLH1, RAD51, CD44, and Nupr1 are well-recognized contributors to pancreatic ductal adenocarcinoma (PDAC) development. Although none of the identified studies directly examined Cr(VI)-associated epigenetic changes in pancreatic tissue or pancreatic cell systems, the convergence of Cr(VI)-induced epigenetic alterations on molecular pathways central to PDAC biology highlights a set of biologically plausible and testable hypotheses linking chromium exposure to pancreatic cancer risk. Together, the available evidence suggests that Cr(VI) exposure could plausibly promote pancreatic carcinogenesis through epigenetic silencing of DNA repair pathways and activation of stress-response and stemness-associated signalling networks. By integrating findings across diverse experimental systems, this review identifies mechanistic intersections between chromium-induced epigenetic dysregulation and established drivers of PDAC. These findings highlight a clear opportunity for targeted investigation of Cr(VI)-associated epigenetic signatures in pancreatic-relevant experimental models and in chromium-exposed human populations. Such studies could determine whether environmentally induced epigenetic alterations contribute to pancreatic cancer susceptibility and may reveal previously under-recognized environmental drivers of pancreatic carcinogenesis.
- Open Access
Genetic Susceptibility to Helicobacter pylori Infection and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomisation Study
Background/Objectives: Pancreatic cancer is one of the most lethal malignancies, with poor survival and few established modifiable risk factors. While Helicobacter pylori (H. pylori) infection is a known cause of gastric cancer, its role in pancreatic cancer remains unclear, with inconsistent observational evidence. Methods: We applied two-sample Mendelian randomisation (2SMR) to assess the causal effect of H. pylori infection on pancreatic cancer risk. Genetic instruments were derived from GWAS data on anti-H. pylori IgG levels in the ALSPAC cohort (n = 4638). Outcomes were pancreatic cancer cases from UK Biobank (936 cases, 400,294 controls) and a combined dataset including UK Biobank, FinnGen, and MVP (5979 cases, 1,234,860 controls). Inverse-variance weighted (IVW) MR was the primary method, supported by MR-Egger, weighted median/mode and MR-PRESSO, with sensitivity analyses for pleiotropy. Results: No significant causal association was observed. IVW ORs were 1.039 (95% CI: 0.846–1.440, p = 0.466) for UK Biobank and 1.077 (95% CI: 0.962–1.206, p = 0.197) for the combined dataset. All complementary methods yielded null results, with no strong evidence of pleiotropy. Conclusions: This 2SMR study found no evidence that H. pylori infection causally increases pancreatic cancer risk. Larger studies with refined exposure measures are warranted.
Open AccessGenetic Susceptibility to Helicobacter pylori Infection and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomisation Study
Background/Objectives: Pancreatic cancer is one of the most lethal malignancies, with poor survival and few established modifiable risk factors. While Helicobacter pylori (H. pylori) infection is a known cause of gastric cancer, its role in pancreatic cancer remains unclear, with inconsistent observational evidence. Methods: We applied two-sample Mendelian randomisation (2SMR) to assess the causal effect of H. pylori infection on pancreatic cancer risk. Genetic instruments were derived from GWAS data on anti-H. pylori IgG levels in the ALSPAC cohort (n = 4638). Outcomes were pancreatic cancer cases from UK Biobank (936 cases, 400,294 controls) and a combined dataset including UK Biobank, FinnGen, and MVP (5979 cases, 1,234,860 controls). Inverse-variance weighted (IVW) MR was the primary method, supported by MR-Egger, weighted median/mode and MR-PRESSO, with sensitivity analyses for pleiotropy. Results: No significant causal association was observed. IVW ORs were 1.039 (95% CI: 0.846–1.440, p = 0.466) for UK Biobank and 1.077 (95% CI: 0.962–1.206, p = 0.197) for the combined dataset. All complementary methods yielded null results, with no strong evidence of pleiotropy. Conclusions: This 2SMR study found no evidence that H. pylori infection causally increases pancreatic cancer risk. Larger studies with refined exposure measures are warranted.
- Open Access
The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer
Background/Objectives: There is conflicting data on which factors predict progression events in active surveillance for early prostate cancer. Here, we explored the value of different clinicopathological variables and whether progression endpoint definitions impact predictive utility. Methods: Clinicopathological variables were extracted from the STRATified CANcer Surveillance (STRATCANs) prospective AS database and included biopsy features (core positivity, cancer core length, and percentage core involvement) and MRI features (Likert score, lesion size, and location), as well as baseline PSA density [PSAd] and Cambridge Prognostic Group (CPG). These were tested against AS endpoint definitions of (1) progression to ≥CPG3, (2) any pathological progression and two definitions from the literature, (3) ≥GG3 or change to treatment, and (4) ≥GG4, metastasis or cancer-related mortality. Predictors were assessed using regression analysis. Results: Data from 296 men were included (median age, 66; follow-up, 5 years). Progression per definition (1–4) occurred in 46 (15.5%), 54 (18.2%), 84 (28.4%), and 10 (3.4%) men. In univariate analysis using Definition 1, no biopsy parameter was independently predictive of progression, while the MRI Likert score (p = 0.02) was the only significant imaging parameter. For Definition 2, core positivity (p = 0.003) and MRI Likert score (p = 0.01) were significant predictors in univariate analyses, while for Definition 3, tumour core length (p = 0.005), core positivity (p = 0.002), and MRI Likert score (p = 0.003) were all predictive in univariate analyses. In multivariate analysis, however, the only consistent independent predictor was PSAd, regardless of endpoint definition. No variables predicted Definition 4 progression. Conclusions: AS endpoint selection appears to define which variables predict progression. Using progression to ≥CPG 3 as an unambiguous AS endpoint, neither biopsy nor MRI variables added incremental value in predicting progression. PSAd, however, appears to be a robust and independent generalisable progression predictor.
Open AccessThe Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer
Background/Objectives: There is conflicting data on which factors predict progression events in active surveillance for early prostate cancer. Here, we explored the value of different clinicopathological variables and whether progression endpoint definitions impact predictive utility. Methods: Clinicopathological variables were extracted from the STRATified CANcer Surveillance (STRATCANs) prospective AS database and included biopsy features (core positivity, cancer core length, and percentage core involvement) and MRI features (Likert score, lesion size, and location), as well as baseline PSA density [PSAd] and Cambridge Prognostic Group (CPG). These were tested against AS endpoint definitions of (1) progression to ≥CPG3, (2) any pathological progression and two definitions from the literature, (3) ≥GG3 or change to treatment, and (4) ≥GG4, metastasis or cancer-related mortality. Predictors were assessed using regression analysis. Results: Data from 296 men were included (median age, 66; follow-up, 5 years). Progression per definition (1–4) occurred in 46 (15.5%), 54 (18.2%), 84 (28.4%), and 10 (3.4%) men. In univariate analysis using Definition 1, no biopsy parameter was independently predictive of progression, while the MRI Likert score (p = 0.02) was the only significant imaging parameter. For Definition 2, core positivity (p = 0.003) and MRI Likert score (p = 0.01) were significant predictors in univariate analyses, while for Definition 3, tumour core length (p = 0.005), core positivity (p = 0.002), and MRI Likert score (p = 0.003) were all predictive in univariate analyses. In multivariate analysis, however, the only consistent independent predictor was PSAd, regardless of endpoint definition. No variables predicted Definition 4 progression. Conclusions: AS endpoint selection appears to define which variables predict progression. Using progression to ≥CPG 3 as an unambiguous AS endpoint, neither biopsy nor MRI variables added incremental value in predicting progression. PSAd, however, appears to be a robust and independent generalisable progression predictor.
- Open Access
Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
Open AccessThreshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
- Open Access
Risk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study
Aim: The recently updated steatotic liver disease (SLD) nomenclature provides a refined classification accounting for both metabolic dysfunction and alcohol exposure. However, the relationship between SLD subtypes and upper gastrointestinal (UGI) cancer risk remains unclear. Methods: We analyzed 456,367 UK Biobank participants, categorizing them into non-SLD, metabolic dysfunction-associated steatotic liver disease with no alcohol (MASLD1), MASLD with minimal alcohol use (MASLD2), metabolic dysfunction-associated alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD) groups. Cox proportional hazards models estimated cancer risks over a median 13-year follow-up, with histologic subtype-specific analyses. Results: Compared to non-SLD, esophageal cancer risk was significantly elevated in all SLD groups with any alcohol consumption (MASLD2, MetALD, and ALD), but not in purely metabolic SLD without alcohol (MASLD1). This association was driven by adenocarcinoma subtype, with hazard ratios ranging from 1.67 to 1.80 in alcohol-exposed SLD groups. For gastric cancer, elevated risk was observed primarily in ALD and MetALD groups, affecting intestinal-type cancers. Squamous cell esophageal cancer and non-intestinal gastric cancer showed no significant associations. Conclusions: Upper GI cancer risk in SLD patients is significantly modified by alcohol consumption, with combined metabolic dysfunction and alcohol exposure conferring the highest risks for esophageal adenocarcinoma and intestinal-type gastric cancer. Clinically, these findings suggest that SLD patients with any level of alcohol consumption require heightened cancer surveillance. Even minimal alcohol intake substantially increases cancer risk in metabolically compromised individuals, supporting alcohol reduction as a key preventive strategy.
Open AccessRisk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study
Aim: The recently updated steatotic liver disease (SLD) nomenclature provides a refined classification accounting for both metabolic dysfunction and alcohol exposure. However, the relationship between SLD subtypes and upper gastrointestinal (UGI) cancer risk remains unclear. Methods: We analyzed 456,367 UK Biobank participants, categorizing them into non-SLD, metabolic dysfunction-associated steatotic liver disease with no alcohol (MASLD1), MASLD with minimal alcohol use (MASLD2), metabolic dysfunction-associated alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD) groups. Cox proportional hazards models estimated cancer risks over a median 13-year follow-up, with histologic subtype-specific analyses. Results: Compared to non-SLD, esophageal cancer risk was significantly elevated in all SLD groups with any alcohol consumption (MASLD2, MetALD, and ALD), but not in purely metabolic SLD without alcohol (MASLD1). This association was driven by adenocarcinoma subtype, with hazard ratios ranging from 1.67 to 1.80 in alcohol-exposed SLD groups. For gastric cancer, elevated risk was observed primarily in ALD and MetALD groups, affecting intestinal-type cancers. Squamous cell esophageal cancer and non-intestinal gastric cancer showed no significant associations. Conclusions: Upper GI cancer risk in SLD patients is significantly modified by alcohol consumption, with combined metabolic dysfunction and alcohol exposure conferring the highest risks for esophageal adenocarcinoma and intestinal-type gastric cancer. Clinically, these findings suggest that SLD patients with any level of alcohol consumption require heightened cancer surveillance. Even minimal alcohol intake substantially increases cancer risk in metabolically compromised individuals, supporting alcohol reduction as a key preventive strategy.
- Open Access
Charity-Provided Community-Based PSA Testing for Assessment of Prostate Cancer Risk in the UK: Clinical Implications and Future Opportunities
Background: Prostate cancer is the most common malignancy among UK men, yet the lack of a national screening program creates disparities in early detection. PSA testing during primary care is inconsistent, limiting timely diagnosis. The Graham Fulford Charitable Trust (GFCT) and its associated support groups offer community-based PSA testing to help bridge this gap. Objectives: This study evaluates GFCT’s historical testing records and a participant survey (2021–2024) to assess their community-based PSA testing program, which is widely used and offers shared decision support. Additionally, we examine the GFCT’s alignment with emerging initiatives such as the UK TRANSFORM trial and other PSA screening developments across Europe and the USA. Methods: The GFCT systematically collects PSA testing data, conducting over 50,000 tests annually. The study assesses the performance of their traffic light scoring system and a previously defined combination algorithm, “Riskman”, which incorporates PSA, PSAft%, and age to classify individuals into risk categories. Multivariable logistic regression was used to evaluate and compare the predictive performance of each approach. Results: Based on the self-reported data in the survey, the GFCT’s traffic light system—using age-specific PSA thresholds to assign green, amber, or red risk—showed good predictive ability. Men in the red group had over 15-fold increased odds of clinically significant cancer (Grade Group ≥ 3) compared to those in the green group. While the Riskman score achieved a higher AUC (0.84 vs. 0.76), both tools were effective in identifying high-risk individuals. Conclusions: This study highlights the GFCT’s role in improving access to PSA screening and integrating practical risk stratification. Its alignment with evolving screening initiatives demonstrates the value of community-based, data-driven approaches for earlier detection of aggressive prostate cancer.
Open AccessCharity-Provided Community-Based PSA Testing for Assessment of Prostate Cancer Risk in the UK: Clinical Implications and Future Opportunities
Background: Prostate cancer is the most common malignancy among UK men, yet the lack of a national screening program creates disparities in early detection. PSA testing during primary care is inconsistent, limiting timely diagnosis. The Graham Fulford Charitable Trust (GFCT) and its associated support groups offer community-based PSA testing to help bridge this gap. Objectives: This study evaluates GFCT’s historical testing records and a participant survey (2021–2024) to assess their community-based PSA testing program, which is widely used and offers shared decision support. Additionally, we examine the GFCT’s alignment with emerging initiatives such as the UK TRANSFORM trial and other PSA screening developments across Europe and the USA. Methods: The GFCT systematically collects PSA testing data, conducting over 50,000 tests annually. The study assesses the performance of their traffic light scoring system and a previously defined combination algorithm, “Riskman”, which incorporates PSA, PSAft%, and age to classify individuals into risk categories. Multivariable logistic regression was used to evaluate and compare the predictive performance of each approach. Results: Based on the self-reported data in the survey, the GFCT’s traffic light system—using age-specific PSA thresholds to assign green, amber, or red risk—showed good predictive ability. Men in the red group had over 15-fold increased odds of clinically significant cancer (Grade Group ≥ 3) compared to those in the green group. While the Riskman score achieved a higher AUC (0.84 vs. 0.76), both tools were effective in identifying high-risk individuals. Conclusions: This study highlights the GFCT’s role in improving access to PSA screening and integrating practical risk stratification. Its alignment with evolving screening initiatives demonstrates the value of community-based, data-driven approaches for earlier detection of aggressive prostate cancer.